window.pageData = {"stock":{"_id":3000000012981,"stockCode":"012981","shortName":"华夏创新医药龙头混合A","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50030000","tickerId":50030000,"name":"华夏基金管理有限公司"},"managers":[{"name":"王泽实","stockType":"fund_manager","stockCode":"db20762219","exchange":"fm","tickerId":232619209450}],"hotMetrics":{"fss":{"stockId":3000000012981,"type":"fss","f_s_s_d":"2024-06-29T16:00:00.000Z","f_ins_h_s_r":0.0005,"f_ins_h_s_r_c_hy":-0.0005,"f_ins_h_s_r_c_1y":-0.00039999999999999996,"f_ind_h_s_r":0.9995,"f_ind_h_s_r_c_hy":0.0004999999999999449,"f_ind_h_s_r_c_1y":0.00040000000000006697,"f_h_a":3526,"f_h_s_a":32886,"last_data_date":"2025-06-29T16:00:00.000Z"},"fpr":{"stockId":3000000012981,"type":"fpr","f_p_r_fys_ssc":8993,"f_p_r_fys_ssrp":0.4627446619217082,"f_p_r_m1_ssc":9195,"f_p_r_m1_ssrp":0.8592560365455733,"f_p_r_m3_ssc":9062,"f_p_r_m3_ssrp":0.32281205164992827,"f_p_r_m6_ssc":8755,"f_p_r_m6_ssrp":0.7250399817226411,"f_p_r_y1_ssc":8330,"f_p_r_y1_ssrp":0.616280465842238,"f_p_r_y2_ssc":7719,"f_p_r_y2_ssrp":0.4901528893495724,"f_p_r_y3_ssc":6903,"f_p_r_y3_ssrp":0.6151840046363373,"f_cagr_p_r_fs_ssc":9144,"f_cagr_p_r_fs_ssrp":0.8853767909876408},"fp":{"stockId":3000000012981,"type":"fp","f_p_r_fys":0.06293706293706292,"f_p_r_m1":0.007734806629834168,"f_p_r_m3":0.033076574535569,"f_p_r_m6":0.010414358519831968,"f_p_r_y1":0.18426178418387318,"f_cagr_p_r_fs":-0.02002945738467954,"f_p_r_d1":-0.005793742757821518,"f_p_r_y2":0.3443396226415101,"f_p_r_y3":0.12676056338028197,"last_data_date":"2026-04-29T16:00:00.000Z"},"ff":{"stockId":3000000012981,"type":"ff","f_m_f":1052071,"f_m_f_r":0.012,"f_c_f":175345,"f_c_f_r":0.002,"f_m_a_c_f":1227416,"f_m_a_c_f_r":0.014,"f_m_c_f_d":"2024-06-29T16:00:00.000Z","f_c_fr":0.002,"f_fr_d":"2025-06-29T16:00:00.000Z","f_m_fr":0.012,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000012981,"type":"f_nlacan","f_nv_d":"2026-04-29T16:00:00.000Z","f_nv":0.912,"f_nv_cr":0.008403361344537785},"f_as":{"stockId":3000000012981,"type":"f_as","f_tas":125534727.79249999,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000012982,"name":"华夏创新医药龙头混合型证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","exchange":"jj","stockCode":"012982","tickerId":12982,"shortName":"华夏创新医药龙头混合C","currency":"CNY","__csrcFundId":9631,"lastUpdated":"2024-05-16T10:29:31.543Z","inceptionDate":"2021-10-10T16:00:00.000Z","fundCollectionId":4000050030000,"followedNum":0,"status":"normal","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":143618422.93,"setUpShares":143618422.93,"masterFundFlag":null,"activeFundFlag":null,"classificationFlag":null,"closedEnd":null,"etfFundFlag":null,"feederFundFlag":null,"indexFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"pinyin":"hxcxyylthhxzqtzjj","memoNum":1}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":1000000000006990,"holdings":56930,"marketCap":23122518,"netValueRatio":0.0889,"quarterlyChange":0.17287098419173907,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":688331,"holdings":169585,"marketCap":21837460,"netValueRatio":0.084,"quarterlyChange":0.6553541586322154,"stock":{"name":"荣昌生物","exchange":"sh","stockType":"company","stockCode":"688331","tickerId":688331}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":1000000000001801,"holdings":262329,"marketCap":19664825,"netValueRatio":0.0756,"quarterlyChange":0.11344262295081897,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":2294,"holdings":255100,"marketCap":15640181,"netValueRatio":0.0602,"quarterlyChange":0.23733602421796118,"stock":{"stockCode":"002294","exchange":"sz","stockType":"company","tickerId":2294,"name":"信立泰"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":1000000000001093,"holdings":1776000,"marketCap":14269884,"netValueRatio":0.0549,"quarterlyChange":0.07947805456702262,"stock":{"stockCode":"01093","exchange":"hk","stockType":"company","tickerId":1093,"name":"石药集团"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":2653,"holdings":239023,"marketCap":12974168,"netValueRatio":0.0499,"quarterlyChange":0.057677318784099096,"stock":{"stockCode":"002653","exchange":"sz","stockType":"company","tickerId":2653,"name":"海思科"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":300765,"holdings":395733,"marketCap":12568480,"netValueRatio":0.0483,"quarterlyChange":-0.11948988078735767,"stock":{"stockCode":"300765","exchange":"sz","stockType":"company","tickerId":300765,"name":"新诺威"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":1000000000009926,"holdings":101286,"marketCap":11643847,"netValueRatio":0.0448,"quarterlyChange":0.1522123893805305,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":600276,"holdings":203514,"marketCap":11238043,"netValueRatio":0.0432,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000012981,"stockId":1000000000002162,"holdings":200000,"marketCap":10719013,"netValueRatio":0.0412,"quarterlyChange":0.1356407857811035,"stock":{"stockType":"company","exchange":"hk","stockCode":"02162","tickerId":2162,"name":"康诺亚-B"}}],"lastFsMetrics":{"latestTurnoverRate":5.155231894196204,"latestTurnoverRateDate":"2025-06-29T16:00:00.000Z"}},"list":[{"_id":"69e8eb8d1398d79843fe93f1","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000012981,"sao":"2026年一季度，医药板块呈现震荡走势，尤其在国际关系出现较大不确定性的背景下，医药板块跟随整体市场调整。我们仍然认为创新药方向是未来几年医药行业中最具备产业发展逻辑的产业方向。2025年国内创新药企业授权出海金额、项目数均创新高，2026年一季度这一趋势仍然在持续。国内创新药企业经过前期的技术积累和临床经验，在早期研发的项目中已经逐渐展现出良好的全球竞争力。我们认为这一竞争力未来会逐渐转化成中国企业在全球药品版图中的份额。一季度组合继续围绕创新药品方向进行布局，维持了港股创新药的高投资比例。在创新药方向上，我们结合自上而下的产业趋势，通过寻找潜在全球竞争力的重点领域、重点产品来构建组合，着重挖掘产品具备较强创新属性、竞争格局好的公司，关注具备出海潜力的产品的投资机会，争取创造持续的超额收益。","lastUpdated":"2026-04-22T15:38:53.083Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2026年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1480275","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018c2","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-21T16:00:00.000Z","stockId":3000000012981,"sao":"2025年四季度，医药板块出现调整。前期涨幅较大的创新药和研发服务外包板块调整较为明显。我们认为板块的调整是阶段性的，中国医药行业的创新能力提升、在全球范围内竞争力提升依然是驱动行业前进的核心因素。四季度整体的宏观环境仍然存在不确定性，我们看到医药行业的运行相对平稳。政策层面，我们一直认为国家医疗保障局对于创新药品的发展是支持和鼓励的。2025年创新药海外授权的金额再创新高。我们认为未来中国医药企业在全球所占的份额也会逐步提升。四季度，组合继续围绕创新药品方向进行布局，维持了港股创新药的高投资比例。在创新药方向上，我们结合自上而下的产业趋势，着重挖掘产品具备较强创新属性、竞争格局好的公司，关注具备出海潜力的产品的投资机会，争取创造持续的超额收益。","lastUpdated":"2026-03-09T13:48:45.298Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1453945","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018c1","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000012981,"sao":"2025年三季度，医药板块震荡上行，板块主要涨幅在7-8月，其中创新药方向涨幅较为突出，创新产业链CRO、CDMO方向均有不错的表现。9月份开始医药板块整体震荡。板块内其他方向资产价格随着整体市场估值水平提升而有所提升。三季度整体海外宏观环境和国内经济情况都有所好转，我们也动态跟踪国内医疗市场的恢复情况。政策层面，我们一直认为国家医疗保障局对于创新药品的发展是支持和鼓励的。结合中报披露的情况看，我们注意到在医药行业平稳增长的背景下，创新药及其产业链上下游这一细分方向的增速是最快的。三季度我们的组合继续围绕创新药品方向进行布局，维持了港股创新药的高投资比例。在创新药方向上，我们关注创新药出海的投资机会，这代表企业的产品在全球范围内具备一定的技术优势。","lastUpdated":"2026-03-09T13:48:45.295Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2025年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1379601","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018c0","date":"2025-06-29T16:00:00.000Z","stockId":3000000012981,"sao":"2025年上半年，全球宏观和经济形势出现分化。美国经济在经历前期的高通胀与货币政策紧缩后，增速放缓，美元表现较弱。国内经济整体平稳，虽然在二季度面临外部关税压力，但依然展现出比较好的韧性。权益市场方面，宽基指数平稳，结构化行情明显。医药板块整体表现较好，其中创新药方向表现更为突出。上半年整体医保基金的收支情况稳定，医药行业展现出刚性需求的特点。政策层面，我们一直认为国家医疗保障局对于创新药品的发展是支持和鼓励的。从业绩角度出发，创新药这一细分板块的增速是最快的。上半年，国内创新药产品对外授权事件频发，激发市场对国产创新药出海能力的信心。本基金继续围绕创新药品方向进行布局，维持了港股创新药相对较高的投资比例，在创新药方向上，我们关注创新药出海的投资机会，这代表企业的产品在全球范围内具备一定的技术优势。","declarationDate":"2025-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.292Z","mo":"展望2025年下半年，我们对医药板块的表现持乐观的态度。政策方面，创新药和创新医疗器械产业支持政策陆续落地，医疗设备更新逐渐推进，都将给行业带来积极影响。中长期看，老龄化带来的诊疗需求和技术创新拉动的产业升级将给医药行业带来稳定的增长。本基金会聚焦于创新和出海的方向，寻找投资机会。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1347325","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018bf","date":"2025-03-30T16:00:00.000Z","stockId":3000000012981,"sao":"2025年一季度，内外部的宏观经济环境比较稳定。权益市场方面，宽基指数表现平淡，结构化行情明显。医药板块在一季度表现较好。一季度整体医保基金的收支情况稳定，医药行业展现出刚性需求的特点。政策层面，我们一直强调国家医疗保障局对于创新药品、医疗器械的发展是支持和鼓励的，我们也看到了相应政策的推进。同时，政府工作报告也提到了进一步优化药品集采政策。细分行业上，刚需药品表现出较好的经营韧性，消费医疗有所恢复，创新药仍然是增速最快的子领域，医疗设备的招标采购也逐渐恢复正常。这也是一季度医药板块表现较好的原因。一季度本基金继续围绕创新药品、医院刚需治疗性产品方向进行布局，并增加了部分港股创新药的投资比例。在创新药方向上，我们关注创新药出海的投资机会，这代表企业的产品在全球范围内具备一定的技术优势。","declarationDate":"2025-04-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.289Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2025年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1271344","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018be","date":"2024-12-30T16:00:00.000Z","stockId":3000000012981,"sao":"2024年，中证医药指数整体呈现下跌趋势，仅在三季度末跟随指数有所反弹。回顾全年，宏观经济呈现出缓慢恢复的态势，但依然面临较多不确定因素。三季度末，央行等多部门密集推出一系列经济、货币等政策，扭转了市场的悲观预期。2024年，伴随着经济的压力，基本医疗保险筹资端增速出现放缓趋势，全年医保资金保持略有结余的状态。结构上，我们看到创新药依然是政策明确支持的方向。创新药医保谈判入选率和价格较好，商业健康保险作为多元化支付方式正在快速发展。医药行业医疗腐败集中整治工作仍然在推进之中，对行业增速产生影响。我们认为，医疗领域的“反腐”工作，长期看有利于行业净化经营环境，对行业健康发展是有利的，尤其是对于创新属性比较强的创新药、医疗器械等方向。伴随国内人口老龄化的进程，医疗的需求是刚性增长的，随着医保的不断发展，支付端也具备了相应的支付能力。2024年，本基金依然聚焦在创新药方向，布局具备全球竞争力和研发进度领先的创新药企业。","declarationDate":"2025-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.286Z","mo":"展望2025年，我们对医药板块的表现持乐观态度。多元化的医疗支付体系正在逐渐形成，商业健康保险建立对应的商保药品目录（丙类目录），这对于医疗行业是增量需求。持续一年多的“医疗反腐”对于行业的影响已经逐渐减弱。我们也观察到行业一些积极的变化，很多创新药企业经过多年的研发积累逐渐进入到商业化落地阶段，中国创新药的研发数量和质量都有大幅度提升，成为全球新药研发的重要角色。我们将继续在创新药及创新药产业链方向上积极寻找投资机会，结合景气度和估值，选择优质标的，努力为投资者创造超额回报。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1251401","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018bd","date":"2024-09-29T16:00:00.000Z","stockId":3000000012981,"sao":"三季度国内权益市场主要指数上涨。9月末，央行宣布创设新的货币政策工具支持股票市场的发展，中央政治局会议也提出加力推出增量政策，努力完成全年经济发展目标。9月末主要指数快速回升。医药板块全年跌幅也大幅度收窄。医疗行业反腐经历了一年多时间，未来将进入常态化阶段。从长期角度看，我们认为医疗反腐有利于医药行业正本清源，实现高质量发展。国务院常务会议审议通过了《全链条支持创新药发展实施方案》，显示在政策层面对于创新药的支持。三季度组合依然延续在创新药、创新医疗器械、医院内刚需治疗产品等方向上的布局，在多个创新研发方向上如ADC、减肥药、抗体药物等领域积极寻找投资机会。我们保持了港股配置比例，港股的部分医药公司从研发到估值都具备了不错的性价比。在政策支持下，国内创新药行业经过几年的发展和沉淀，行业格局已经渐渐清晰。部分创新药物具备了全球领先的潜力。近些年出现的新产品如免疫治疗、ADC药物、减肥药、小核酸药物等也给创新药市场带来新的活力。我们也看到部分医疗器械产品已经具备了全球竞争力，并在海外市场竞争中逐渐提升市场份额，组合增加了相关领域出海公司的配置。","declarationDate":"2024-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.284Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2024年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1175672","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018bc","date":"2024-06-29T16:00:00.000Z","stockId":3000000012981,"sao":"2024年上半年，股票市场出现较大波动，沪深300指数上涨0.89%，中证医药指数下跌20.15%。上半年医药板块业绩增速整体上较为平淡，一方面因为医疗腐败集中整治工作仍在推进，另一方面原因是去年上半年疫情后诊疗需求的集中释放带来的高基数影响。报告期内，本基金继续聚焦于创新药以及创新医疗器械的配置方向，并在多个创新研发方向上，如ADC、减肥药、抗体药物等领域积极寻找投资机会。我们保持了的港股配置比例，港股医药板块的部分创新药公司已经具备了不错的投资性价比。国内的创新药行业经历了过去几年的快速发展，格局已经渐渐清晰，部分创新产品在国内已经进入商业化阶段，在海外也有授权合作的积极进展。国产医疗器械和设备逐渐进入高端医疗领域，在高值耗材的集采和医院招标采购后进入了放量周期。","declarationDate":"2024-07-17T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.281Z","mo":"展望2024年下半年，我们对医药板块的表现持乐观的态度。随着诊疗的恢复、新产品的放量以及去年下半年因为医疗腐败集中整治工作带来的低基数，医药行业下半年业绩增长有望较上半年提速。政策方面，各地创新药产业支持政策陆续落地，医疗设备更新逐渐推进，都将给行业带来积极影响。中长期看，老龄化带来的诊疗需求和技术创新拉动的产业升级将给医药行业带来稳定的增长。我们会聚焦于创新药和创新医疗器械，发现新的产品周期和技术周期，寻找投资机会。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1144809","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018bb","date":"2024-03-30T16:00:00.000Z","stockId":3000000012981,"sao":"一季度国内权益市场主要指数基本走平，过程中波动较大，指数先跌后涨。医药板块在一季度也经历了较大幅度的调整。由于医疗反腐的影响和去年疫情带来的基数效应，板块内公司一季度收入增速出现分化。长期看，医疗反腐有利于医药行业回归医疗本质，实现高质量发展。医疗政策方面，创新药品、创新医疗器械一直是政策鼓励、支持的方向。一季度我们仍然坚持在创新药、创新医疗器械、院内刚需诊疗产品等方向上进行布局，并在多个创新研发方向上如ADC、减肥药、抗体药物等领域积极寻找投资机会。我们仍然维持了一定程度的港股配置比例，我们认为港股医药板块的部分股票已经具备了不错的投资价值。国内的创新药行业经过几年的发展和政策的支持，格局已经渐渐清晰。部分创新产品临近上市或者已经进入商业化阶段。全球范围内，近些年出现的新产品如ADC药物、减肥药、阿尔兹海默、小核酸药物等也给创新药市场带来新的活力。国产的高端医疗设备、耗材逐渐进入高等级医院，医疗器械的国产替代和产业升级也正在逐步推进。这些依然是我们看好的方向。","declarationDate":"2024-04-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.278Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2024年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1067388","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018ba","date":"2023-12-30T16:00:00.000Z","stockId":3000000012981,"sao":"2023年国内经济在疫情后逐渐恢复。恢复的节奏和幅度与市场的预期仍然有差距。经济总量层面呈现弱复苏，增长转向高质量发展。在经济增长预期较弱、流动性宽松的背景下，整体市场呈现震荡走势。下半年，地产政策层面我们看到了一些积极的变化，逆周期的宏观调节力度逐渐增加，中央经济工作会议强调2024年要“稳中求进”“以进促稳”“先立后破”。海外经济政治环境依然不稳定，俄乌地缘冲突仍在继续。美国通胀水平较高，美元持续加息，这也对国内的权益市场造成了一定程度的影响。医药行业在2023年也经历了由疫情到疫后复苏的过程。医院诊疗在二季度开始逐渐恢复正常。三季度医药行业受到了医疗反腐事件的影响，四季度逐渐在恢复中，临床效果更优的产品和刚性产品恢复更快。创新药依然是政策鼓励的方向，这一点我们在去年年报中已经提及。年底的创新药医保谈判，续约产品和新进入产品都有了明确的价格预期。组合层面，我们依然坚持原有的投资框架。沿着产业趋势的发展，我们依然布局在创新药及产业链、创新医疗技术等方向上。我们认为医疗反腐活动对行业短期影响有限，长期对于行业高质量发展将起到积极作用。我们一直认为医药是一个长期值得投资的行业，中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。政策层面，医保筹资端、药品准入审批政策，以及医保支付，都支持医药行业长期向好发展。好的产品、技术和服务仍然是创造行业需求的重要因素。我们坚持在创新药品、技术方向进行布局，力求给投资者创造稳定的回报。","declarationDate":"2024-01-18T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.275Z","mo":"展望2024年，我们对医药行业持乐观态度。一方面医疗反腐对行业造成的阶段性影响在逐渐减弱，医疗诊疗刚性需求的稳定性将逐渐体现。另外我们也看到行业处于一个新的技术发展周期，很多创新药品、技术不断涌现，给医药行业的供给端带来了新的活力。行业政策端，我们认为过去几年审批准入、医保支付等政策已经成熟，行业发展有了明确的方向和稳定的预期。我们仍然将从创新药品及产业链、创新医疗技术、创新医疗设备和器械等方向积极寻找投资机会。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1049174","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b9","date":"2023-09-29T16:00:00.000Z","stockId":3000000012981,"sao":"三季度国内权益市场震荡下行。国内经济恢复的程度和节奏成为投资者关注的焦点。医药行业在三季度受到医疗反腐的影响。在此过程中，行业的收入增速出现了一定程度的波动。我们认为，此次由卫健委牵头的全国医药领域腐败问题整治，有利于长期医药行业正本清源，回归到医疗的本质上。短期受到医疗反腐的冲击，医疗板块在三季度出现波动。但正如前文所说，行业的规范有利于长期的发展，我们也看到板块在调整一段时间后逐渐企稳回升。三季度我们增持了部分创新药、创新药产业链以及创新医疗器械，并在减肥药等医疗消费方向寻找投资机会。同时我们增加了港股的配置比例，我们认为港股的部分创新药公司已经具备了不错的投资价值。国内的创新药企业经过过去几年的发展和政策的支持，格局已经渐渐清晰。部分创新产品临近上市或者已经进入商业化阶段。全球范围内，近些年出现的新产品如ADC药物、减肥药、阿尔兹海默药物等也给创新药市场带来新的活力。国产的高端医疗设备、耗材逐渐进入高等级医院，医疗器械的国产替代也正在逐步推进。中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。在医保资金内，创新药、创新器械的占比逐渐增大。","declarationDate":"2023-10-23T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.272Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2023年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=986593","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b8","date":"2023-06-29T16:00:00.000Z","stockId":3000000012981,"sao":"2023年上半年国内权益市场呈现震荡走势。国内疫情逐渐平稳过去，经济也逐渐恢复。两会召开为国内经济高质量发展指明了方向，国家机构改革也为未来经济发展提供了改革活力。医药板块在上半年出现了一定幅度的调整，一方面源于市场对于经济复苏程度的担心，另一方面因为国内医药产业发展速度出现了暂时的低迷。上半年我们继续加大创新药、创新医疗器械的配置比例。国内的创新药经历了过去几年的快速发展，格局已经渐渐清晰，部分创新产品临近上市或者已经进入商业化阶段。头部企业在经历过2018年以来的药品集采之后，仿制药的部分也逐渐走出低谷。国产医疗器械和设备，也有部分产品迈进了高端领域，在高值耗材的集采和医院招标采购后进入了放量周期。中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。在医保资金内，创新药、创新器械的占比也逐渐增大。中长期维度，我们认为持续的创新是医药行业发展的动力。在组合中，我们重点配置了处方药和医疗器械板块，尤其是有创新产品商业化的药品和器械公司。","declarationDate":"2023-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.269Z","mo":"站在目前时点，展望2023年下半年，我们对医药板块的表现持积极乐观的态度。一是疫情的影响正在逐渐过去，就医需求仍然在逐步恢复的过程中；二是在政策层面，鼓励创新产品的政策也在不断优化实施。从医保支付政策到审评审批政策，我们都看到了对于创新产品的支持。医药行业的需求来源于人类对于健康和生命的不断追求。未来一段时间，我们将看到国内的一些原创式创新或者改进式创新产品在国内上市，解决国内医疗可及性的需求。我们将更严格地筛选公司，从企业中长期基本面出发，寻找高质量、确定性的成长型医药企业。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=957759","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b7","date":"2023-03-30T16:00:00.000Z","stockId":3000000012981,"sao":"一季度国内权益市场震荡上行。国内疫情逐渐平稳过去，经济也逐渐恢复。海外资金面整体偏暖。在这样的背景下，一季度医药板块也震荡上行。强复苏预期的创新药及产业链、恢复较快的刚需医疗场景均有表现。一季度我们延续去年4季度的运作方向，继续加大创新药、创新器械以及创新产业链的配置比例。国内的创新药经历了过去几年的发展，格局已经渐渐清晰，部分产品也临近上市或者已经进入商业化阶段。中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。在医保资金内，创新药、创新器械的占比也逐渐增大，集采后的仿制药金额占比逐渐减小。我们延续之前的判断，认为2023年医药板块的投资机会大过风险。在经济复苏后，医院的刚需医疗消费场景将逐渐恢复。中长期维度，我们认为持续的创新是医药行业发展的动力，也是医药行业收益的主要来源。在组合中，我们重点配置了创新产品及其产业链，以及疫情恢复后的刚需医疗场景、刚需用药和耗材。细分行业上，我们继续持有创新药、创新器械、创新产业链的CRO/CDMO以及部分中药创新。","declarationDate":"2023-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.266Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2023年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=881441","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b6","date":"2022-12-30T16:00:00.000Z","stockId":3000000012981,"sao":"2022年的全球经济环境不稳定，部分地区发生地缘政治冲突。在这样的情况下，权益市场发生了比较大幅度的震荡。2022年国内仍然受到疫情的影响，尤其是经济活动受到的波及更大。全球政治经济局势的不确定性，导致供给端受到冲击，部分大宗商品的价格出现上行，也部分加剧了经济情况的恶化。下半年，海外的需求出现了一定程度的回落，进而也引发了对经济的担忧。在这样的背景下，国内在政策端出现了一些积极的变化，支持力度逐渐增加。在新能源车等新兴领域之外，房地产方面对于严格的限制政策也进行了一些修正。在年底疫情放开的情况下，中央经济工作会议强调“加大宏观政策调节力度”等促进经济发展的提法，提振经济的需求端。医药板块在2022年也受到了上述宏观经济背景的影响。部分估值较高或受到地缘政治影响的子行业出现了明显的调整。提供各类防疫物资、药品的板块表现相对较好。政策方面，政策对传统中医中药较为“呵护”。医疗高端装备在年末有贴息贷款政策加持。而在药品、器械方向，我们看到了医保局在集采方案上，有了新的调整，对企业来说，可以更合理、科学的制定价格，有助于稳定企业的长期盈利预期，也有助于稳定行业的长期高质量、安全发展。创新药依然是政策鼓励的方向，年底的医保谈判，对于续约规则的明确也让创新药企对价格有了明确的预期。组合层面，我们依然坚持原有的投资框架。沿着产业趋势的发展，我们依然布局在创新及产业链、高端制造升级以及部分低渗透率的医疗消费为主的领域。创新药领域我们除了关注化药、生物药以外，也增加了对于中药创新药的配置。在高值耗材集采政策方案公布后，我们也增加了部分创新医疗器械的配置。我们一直认为医药是一个长期值得投资的行业，中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。政策层面，从药品的审评审批到医保支付，都向提供更好更全面的医疗服务方向倾斜，同时对行业运行方式进行规范。在医药板块调整的过程中，我们坚持在创新、高端制造和医疗消费升级方向进行布局，同时也更加关注医疗健康领域的产业链自主可控，并用更为严苛的标准聚焦在高质量成长的公司上，力求给投资者创造稳定的回报。","declarationDate":"2023-01-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.263Z","mo":"站在目前时点，展望2023年，我们对医药板块的表现持积极乐观的态度。就医需求在过去两年受到一定程度的影响。行业在2023年将经历疫情后的医疗场景恢复。政策方面，2022年对于仿制药集采、高值耗材集采和创新药谈判，都有了更为明确的政策预期，方案也更加合理科学，医保支出下降的同时，保证产品质量，也保证企业能够有支撑长期发展的盈利。医药行业的需求来源于人类对于健康和生命的不断追求。创新药、创新医疗器械，以及创新医疗技术都不断有技术突破。随着中国经济水平和人均收入达到了新的高度，行业存在大量对高质量医疗产品、服务的需求。创新研发经历过去几年的周期，研发立项也更加理性。未来一段时间，我们将看到国内的一些原创式创新或者改进式创新产品在国内上市，解决国内医疗可及性的需求。部分优秀的产品和技术已经开始逐渐走向全球，开始和全球顶尖技术同台竞争市场。国内的基础教育优势将为这一过程提供人才方向的支持，国内的市场也为这一过程提供了一个安全且足够大的市场。地缘政治风险仍然存在，我们将特别关注在国际关系背景下存在“卡脖子技术”的公司或者受到此影响的公司，以寻找投资机会。我们将更严格地筛选公司，从企业中长期基本面出发，寻找高质量、确定性的成长型医药企业。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=867364","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b5","date":"2022-09-29T16:00:00.000Z","stockId":3000000012981,"sao":"三季度医药板块明显回调。医药板块从估值层面已经调整较多，回到了一个合理的水平。同时我们注意到，医药行业仍然保持快速、稳定的内生增长，这在2022年错综复杂的内外部环境下显得尤为难得。三季度，国内的疫情仍然处于局部散发的状态。由于omicron突变株的传染性较强，防疫的工作面临更大的困难。全球范围内，omicron不断有新的突变株产生，叠加地缘政治的不确定性，给全球经济和资本市场都带来了较大的冲击。三季度我们的组合向医药硬科技方面做了一些调整，在坚持原有的投资思路的基础上，增加了创新药、创新器械和创新设备的配置比例。我们认为医药是一个长期值得投资的行业，中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。我们依然延续对于行业的中长期的判断，认为可持续的壁垒或者可持续的创新和进化是行业发展的源动力，也是医药行业收益的主要来源。在组合中，我们重点配置了创新产品及其产业链，并结合当前医院建设周期，增加了医疗相关设备的配置比例。细分行业上，我们继续持有创新药、创新器械、创新产业链的CRO/CDMO以及部分中药创新药。","declarationDate":"2022-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.260Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2022年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=803224","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b4","date":"2022-06-29T16:00:00.000Z","stockId":3000000012981,"sao":"2022年上半年，全球权益市场由于一些突发外部事件，处于高度不确定之中。国内由于omicron新冠病毒突变株带来的部分地区的疫情，也让防疫成为上半年国内的扰动因素。在这样的背景下，国内的资本市场也产生一定的波动，完成经济指标面临较大的压力。在行业上，上半年医药指数表现一般，整体指数仍然在消化估值的过程中。由于过去两年在疫情过程中的流动性宽松，一级市场的投融资热度是极其火热的。随着2021年流动性开始逐渐收紧，投融资数据也面临了阶段性的下行趋势。大量依靠融资的biotech面临资金的压力，而在创新研发上变得谨慎。过去几年，随着中国药品评审政策的改革以及医保支付的变化，国内出现了一波投资创新药的浪潮，也吸引着全球人才回国创业。随着供给端的增加，支付端受到医保的约束，过高的泡沫开始逐渐褪去。我们认为这是一个去伪存真的过程，创新并不是为了赚快钱，而是踏踏实实做出满足更好标准临床需求的me-better或者全球性创新。政策端，从支付方的角度，医保对于创新药仍然是鼓励的，民营医疗服务也没有出现一刀切的负面政策。我们一直认为医药是一个长期值得投资的行业，中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。创新，仍然是医药行业发展的源动力。虽然行业面临着各种问题，但我们认为行业发展的方向没有变，即通过创新满足更好的临床需求，而中间的过程只是行业发展中必然会出现的一些波动。同时，随着人民收入水平的提高，在消费医疗领域，行业也存在很多消费升级的投资机会。因此，我们在上半年重点布局创新药、创新药研发外包创业链（CRO、CDMO等）、创新医疗器械、医美等子行业。我们将持续积极的寻找具备创新属性的高增长企业，逐渐增加到组合中，力求给投资者创造稳定的回报。","declarationDate":"2022-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.257Z","mo":"站在目前时点，展望下半年，我们认为俄乌冲突可能逐渐接近尾声。由此引发的高通胀可能也会逐渐平抑。由于美国经济刺激的逐渐收尾，全球的经济增长会面临较大的压力。国内的经济处于omicron新冠突变毒株引发的局部疫情后的复苏之中。因此我们看好在这一背景下下半年的医院端和消费医疗端的恢复。创新领域，一级市场的投融资平淡已经经历了一段时间，行业还在经历由此引发的阵痛。但是我们对于医药行业的“真创新”依然乐观，只有创新才是激发行业不断前进的要素。我们仍然长期看好医药行业的发展以及医药板块的投资机会。医药行业的需求来源于人类对于健康和生命的不断追求。我们正处在一个行业技术快速发展的时期。从2015 年的药审政策改革到2018年的医保局支付体系形成，国内医药行业进入了创新驱动发展的阶段。同时，中国经济水平和人均收入达到了新的高度，行业存在大量对高质量医疗产品、服务的需求。这将进一步促进企业加大研发投入，进行产品创新。我们依然看好需求端高速发展、拥有良好商业模式、竞争格局清晰或者具备竞争优势的行业和公司，包括创新药/创新医疗器械、创新研发外包服务产业链、医美等方向。我们将更严格的筛选公司，从企业中长期基本面出发，寻找高质量、确定性的高成长。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"270华夏创新医药龙头混合型证券投资基金2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=781867","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b3","date":"2022-03-30T16:00:00.000Z","stockId":3000000012981,"sao":"一季度医药板块呈现触底反弹。首先，医药板块从估值层面已经调整较多，回到了一个合理的水平。其次，医药行业仍然保持快速、稳定的内生增长，这在2022年错综复杂的内外部环境下显得尤为难得。一季度omicron疫情肆虐全球，并在2月份突破香港。3月份开始，国内很多城市也开始经历omicron疫情的冲击。这也印证了我们上个季度的判断，即omicron的传播力非常强，可能对全球的经济造成新一轮的影响。报告期内，我们依然坚持原有的投资思路。我们认为医药是一个长期值得投资的行业，中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。我们适当增加了消费型医疗的配置比例。我们依然延续对于行业的中长期的判断，认为可持续的壁垒或者可持续的创新和进化是行业发展的源动力，也是医药行业收益的主要来源。一季度的组合中，我们重点配置了创新产业链，并增加了具备一定创新壁垒的消费型医疗产品公司。细分行业上，我们继续持有创新药产业链的CRO/CDMO、创新器械等。同时我们也关注到政策上对中医中药行业的鼓励，增加了中药创新药的配置。由于国内疫情在较多的城市发生，我们也适当配置了一定的防疫类方向，作为对于组合的一种保护。","declarationDate":"2022-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.254Z","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2022年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=722442","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aecfbd7fea5b3eb05018b2","date":"2021-12-30T16:00:00.000Z","stockId":3000000012981,"sao":"2021年全球仍然处于新冠疫情的笼罩之下。临近年末，新冠新的突变毒株Omicron席卷全球。除了疫苗之外，新冠药物也成为了研发新的突破点。全球大部分国家选择了与新冠病毒“共存”的防疫策略。这使得经济活动逐渐正常化。在这样的背景下，尽管全球依然保持了相对“宽松”的货币政策，但是美国加息的脚步不断临近。成长类资产出现了一定幅度的回调，医药板块在全年时间维度内经历了明显的先涨后跌。。在国内，医疗方面的政策再次成为市场担心的焦点。同时中医、中药方面，也有一些相对支持、鼓励的政策出现。国内的创新研发，从药品和器械端，都走向了全球化的进程。医疗服务端短期受到国内疫情反复的影响，但是我们认为竞争格局清晰、长期需求好的医疗服务方向仍然是值得关注的。在医疗高端制造领域，国内的制造业优势充分体现，并在疫情过程中逐渐加大。我们一直认为医药是一个长期值得投资的行业，中国的人口老龄化以及经济水平的发展构成了从需求端到支付端对医药行业的长期支撑。在医药板块调整的过程中，我们依然延续之前的投资框架，在创新、高端制造和消费升级方向进行布局，同时也更加关注医疗健康领域的产业链自主可控，并用更为严苛的标准聚焦在高质量成长的公司上。组合重点布局创新药、创新药研发外包创业链（CRO、CDMO等）、医疗装备等子行业。我们将持续积极寻找具备创新属性的高增长企业，逐渐增加组合的丰富度，力求给投资者创造稳定的回报。","declarationDate":"2022-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T13:48:45.251Z","mo":"站在目前时点，展望2022年，我们认为虽然在医疗行业的政策上大家仍然有疑虑，但是我们仍然认为长期医药行业的需求会带来行业的快速发展。我们仍然对医药板块的投资持积极态度。医药行业的需求来源于人类对于健康和生命的不断追求。创新药、创新医疗器械，以及去年取得突破性进展的mRNA疫苗都在相关治疗领域取得了重大的突破。国内医药行业进入了创新驱动发展的阶段。中国经济水平和人均收入达到了新的高度，行业存在大量对高质量医疗产品、服务的需求。这将进一步促进企业加大研发投入，进行产品创新。医疗行业的创新也将逐渐走出国门，走向全球化。同时，中国的人口红利和工程师红利也为技术进步提供了基础。在医药领域越来越多的公司开始在全球产业链分工中具备更强的竞争力。我们依然相信我们的投资框架，看好需求端高速发展、拥有良好商业模式、竞争格局清晰或者具备竞争优势的行业和公司。我们将更严格地筛选公司，从企业中长期基本面出发，寻找高质量、确定性的高成长。珍惜基金份额持有人的每一分投资和每一份信任，本基金将继续奉行华夏基金管理有限公司“为信任奉献回报”的经营理念，规范运作，审慎投资，勤勉尽责地为基金份额持有人谋求长期、稳定的回报。","fund":{"_id":3000000012981,"__csrcFundId":9631,"stockCode":"012981","shortName":"华夏创新医药龙头混合(012981)","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":12981,"currency":"CNY","masterFundFlag":1,"lastUpdated":"2026-04-30T23:34:26.403Z","status":"normal","exchange":"jj","name":"华夏创新医药龙头混合型证券投资基金","fundCollectionId":4000050030000,"followedNum":2,"inceptionDate":"2021-10-10T16:00:00.000Z","masterFundShortName":"华夏创新医药龙头混合","setUpDate":"2021-10-10T16:00:00.000Z","setUpAssetScale":75183011.36,"setUpShares":75183011.36,"pinyin":"hxcxyylthhxzqtzjj","managers":[{"stockCode":"db20762219","stockType":"fund_manager","exchange":"fm","tickerId":232619209450,"name":"王泽实"}]},"announcement":{"linkText":"华夏创新医药龙头混合型证券投资基金2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=711536","linkType":"PDF","source":"csrc_pdf"}}]}